AWD 52-39, or AWD-5239, also known as N,N-diacetoxyethyl-9,10-dihydrolysergamide, is a drug described as a "nootropic" (cognitive enhancer) of the lysergamide family related to lysergic acid diethylamide (LSD) that was never marketed. It was under development by Arzneimittelwerk Dresden, but development was discontinued. The effects of AWD 52-39 in preclinical studies have been reported. It has been described as a serotonin 5-HT2 receptor antagonist. The drug has been found to enhance learning and memory and to produce antidepressant-like effects in rodents. It appears to act upon vascular serotonin receptors. The chemical synthesis and stereochemistry of AWD 52-39 have been described. The drug was first described in the scientific literature by 1989. It reached phase 2 clinical trials for the treatment of cognition disorders prior to the discontinuation of its development.
See also Substituted lysergamide List of investigational cognition and memory disorder drugs 9,10-Dihydro-LSD Nicergoline Dihydroergotoxine Romergoline
References